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1146-108 Association of Major Bleeding With Adverse Clinical 
Outcomes and Length of Stay: A TACTICS TIMI 18 
Substudy 
1146-110 Blinded Adjudication of Reinfarction Following 
Fibrinolysis: Data From the HERO-2 Trial 
Mark K. Jordan, David E. Cohen, Graham C. Wang, Christopher P. Cannon, Eugene 
Braunwald, C. Michael Gibson, The TIMI Study Group, Brigham & Women’s Hospital, 
Boston, MA 
John K. French, John J. Edmond, Philip E. Aylward, Cheuk-Kit Wang, Ralph A. Stewart, 
Barbara F. Williams, lvor L. Gerber, Carmine DePasquale, Rachel O’Connell, John 
Simes, Harvey D. White, for the HERO-2 Investigators, Green Lane Hospital, Auckland, 
New Zealand, Flinders Medical Centre, Adelaide, Australia 
Background: Bleeding complications remain a potentially important contributor to mor- 
bidity and cost I” the treatment of acute coronary syndromes (ACS). We hypothesized 
that bleeding would be associated with disease comorbidites, excess cost, and increase 
length of stay. 
Methods The TACTICS TIMI 18 enrolled 2220 patients with ACS and compared early 
invasrve and conservative management strategies on a background of Tirofiban therapy. 
Major bleeding was defined as a decrease in the blood hemoglobinlevel of at least 5.0 g 
per deciliter, the heed for the transfusion of 2 or more units of blood, the need for coro- 
nary artery bypass grafting (CABG). tamponade during the index hospitalization. 
Results: Major bleeding occurred in 4.4% of all patients. 14.4% of CABG patients, 2.4% 
of non-CABG patients, and 4.7% of PCI patients. Intracranial hemorrhage occurred in 
one patient. Vascular access site bleeding occurred in 0.4% of all patients and in 1.5% of 
PCI patients. Increased age, lower weight, ST deviation, positive troponin status, an 
early invasive strategy, angiography during the initial hospitalization. emergent PCI, and 
CABG were all associated with major bleeding in univariate analysis. Only CABG and 
Age ~65 were independently associated with major bleeding in the multivariate analysis. 
After adjustment for CABG, age>65, positive troponin status, diabetes, and ST deviation, 
major bleeding was independently associated with an increased risk of death at 30 days 
(OR 5.0, p<O.OOi). Major bleeding was associated with $6,596 per patient of excess ini- 
tial hospitalization costs, and 1.2 days per patient increase in length of stay (after adjust- 
ment for potential confounding variables). 
Conclusions: Major bleeding occurred infrequently despite a high rate of invasive revas- 
cularization procedures. Major bleeding is associated with excess costs, increased 
length of stay, and higher mortality. 
1146-109 Renal Insufficiency in the Setting of an Acute Coronary 
Syndrome Is Associated With a Marked Increase in 
Death and Myocardial Infarction at 30 days 
Background: Re-infarction (reMI) is associated with worse outcomes following fibrin- 
olytic therapy and is increasingly a component of the primary endpoint in clinical trials In 
2001, 3 large clinical trials reported that reMl was reduced in patients receiving the 
experimental reperfusion and adjunctive therapies. In HERO-2, which randomized 
patients to receive either intravenous heparin or bivalirudin prior to streptokinase, reMl 
was adjudicated by a Cknical Endpoints Commrttee (CEC) and we report the results of 
reMl adjudication. Methods: Adjudication was performed on data collected by investiga- 
tors according to the following pre-defined criteria: i) ~18 hours from randomization 
(230min chest pain and ZlmV ST elevation in 2 leads), ii) 18 hours from randomzation 
(CK level >2x upper limit of normal (ULN)or CKMB >ULN and >50% above prior base- 
line, iii) in association with percutaneous intervention (CK or CKMB levels z-3x ULN) or iv) 
surgical revascularization (CK or CKMB levels >5x ULN); also in Ii-iv new LBBB or new Q 
waves. Results: Of 722 cases referred for CEC adjudication of reMI, 170 cases (24%) 
reMl was not confirmed for the following reasons: 57 (34%) sufficient data available for 
CEC to determine “no reMI”; 43 (25%) lack of data supplied to confirm reMI; 19 (11%) 
recurrent ST elevation at >18 hours but reperfusion therapy (6 PCI) and no CKfCKMB 
elevation; 16 (9%) died prior to possible CWCKMB level elevations; and 35 (20%) had a 
CEC-adjudicated non-ischemic etiology. 30-day mortalities for adjudicated, investigator- 
reported reMIs, and no reMl were 24%, 27% and 10% (pcO.001) and mortalities for adju- 
dicated reMIs at c96 hours, >96 hours were 28%, and 19% (~~0.04). Rates of reMl dif- 
fered across 5 regrons at (predefined) 96 hours (highest Western Countries 3.2%, lowest 
Eastern Europe 1.5% p<O.oOi), partly reflecting different rates of reMl at cl8 hours 
(highest Asia 1 .l%, lowest Russia 0.23%; pcO.001). Conclusion: Despite prespecified 
criteria for investigators, 24% of cases were adjudicated “no reMI” by the CEC. ReMl var- 
ied markedly by region, especially at c96 hours compared to later than this time after ran- 
domization, and reMl mortality varied over these time periods. 
Mohammed Ghanamah, Joel P. Reginelli, Herbert D. Aronow, Arman T. Askart, Derek P. 
Chew, Deepak L Bhatt, The Cleveland Clinic Foundation. Cleveland, OH 
1146-l 11 Bivalirudin Versus Heparin for Patients With 
Thrombocytopenia 
Timothv D. Henq, Jay H. Traverse, Derek P. Chew, Minneapolis Heart Institute 
Foundation, Minneapolis, MN, Flinders Medical Center, Australia 
Background: Renal insufficiency (RI) is an established predictor of long-term outcome in 
patrents with coronary artery disease. The impact of RI on short-term outcomes following 
hospitalization for an acute coronary syndrome (ACS) remains unknown. We sought to 
investigate whether RI at the time of presentation with an ACS predicted clinical events 
at 30 days. Methods: Using an interventional registry database, 504 patients presenting 
wrth an ACS were grouped into one of four categories based on creatinine clearance 
(CrCI) in mllmin: >90, 60-90, 30-60, and ~30. Patient outcomes were recorded at 30 days 
and 1 year. Results: Using a test of trend and homogeneity, we observed an exponential 
rise in the risk of death and Ml at 30 days for each decrement in renal function (X2=32, 
p~O.O000l)(graph). Patients were then divided into two groups classified as normal 
(CrCIx60) or RI (CrClc60). When compared to normals, patients with renal insufficiency 
suffered a 5-fold excess of death or MI at 30 days (OR 5.23[C.l.=2.57-10.661, 
p<O.OOOOl). Conclusion: The prevalence of RI (defined as CrCIc60) was 28% in this 
ACS population, and conferred a 5fold increased risk of death and Ml at 30 days. The 
prevalence and impact of RI is therefore equal to, or greater than, many of the commonly 
utilized biomarkersfor risk assessment in ACS. This suggests that the presence of RI 
should weigh heavily in the overall risk assessment of ACS patients. 
Background: Patients (Pts) who develop thrombocytopenia (tcp) associated with heparin 
or Ilb/llla inhibitors have increased risk of bleeding events as well as myocardial infarc- 
tion (Ml) and death (Circl999). Pts with relative tcp at baseline are at higher risk to 
develop significant tcp. In a consecutive series, 15.6% of pts with Ml had a platelet (plt) 
count of <150.000 at presentation, increased bleeding and ischemic complications com- 
pared to pts with normal plt counts. Bivalirudin, a direct thrombin inhibitor that does hot 
cause tcp. has been shown to decrease bleeding and ischemic complications compared 
to heparin during PCI. Methods: We compared the outcome of pts with relative tcp in 
1,425 pts treated with bivalirudin vs. heparin during PCI. From a database of 4,763 pts 
enrolled in 5 trials of brvalirudin vs. heparin in conjunction with PCI, 236 (5%) pts had a 
plt count <I 50,000 and 1,425 (29.8%) had a plt count ~200,000 at the time of the PCI. 
Pts treated with bivalirudin had lower incidence of death, MI, revascularization, or major 
hemorrhage (see table). Conclusions: Relative tcp (~200,000) is relatively common even 
for pts enrolled in randomized clinical thals. Pts treated wtih bivalirudin had significantly 
lower incidence of death, MI, revasculanzation. or major hemorrhage. The overall out- 
come and magnitude of benefit with bivalirudln were similar to pts wrth a plt count 
>200,000 at baseline. Relative tcp does not appear to be a risk factor for adverse out- 
come among pts treated with bivalirudin. 
30 
Event Bivalirudin Heparin 0 95%CI 
(rl=745) @=sso) R 
Death, MI, Revascularization or Major 47 (6.3%) 72 (10.6%) 0. 0.39, 
Hemorrhage 57 0.63 
Death or MI 22 (3.0%) 30 (4.4%) 0. 0.38, 
66 1.15 
Revascularization 14 (1.9%) 18 (2.6%) 0. 0.35, 
70 1.43 
Major Hemorrhage 19 (2.6%) 37 (5.4%) 0. 0.26, 
45 0.80 
1146-112 Gender-Specific Risk Factors for Thromboembolic 
Stroke With Acute Myocardial Infarction 
Eric Van De Graaff, Eric A. Shry, Paul D. Frederick, Nathan Every, Mary Blaney, Morris 
Cheeks, Steven R. Steinhubl, Wright Patterson Medical Center, Dayton, OH, Ovation 
Research Group, Highland Park, IL 
Background: Risk factors for nonhemorrhagic cerebrovascular accidents (NHCVA) in the 
setting of myocardral infarction (Ml) have been described. To date no study has evalu- 
ated oender-soacific risk factors for NHCVA. Methods: Analvsis of the National Reaistrv _ _ , 
of Myocardial Infarction (NRMI) 314 databases shows that women are 64% more likely to 
suffer NHCVA with Ml than are men. This difference oersists desoite controllino for 27 
variables using a multivariate model (OR for women vs. men 1.431, 95% Cl 1.285. 
1.593). We analyzed records of 257,637 male and 197,865 female patients with MI found 
in the NRMI 3/4 databases. Of these 997 males (0.388%) and 1250 females (0.636%) 
suffered NHCVA. Females with NHCVA were significantly more likely to be older, have a 
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history of hypertension or heart failure, weigh less; were less likely to use tobacco, have 
a history of bypass surgery; and were less likely to undergo coronary revascularization. 
(P<O.OOOl all). Increased time to revascularlzation. larger infarction size. and worse ejec- 
tion fraction on discharge were more predictive of stroke in men than in women (table). 
When multivariate analysis was performed of populations individually, these markers 
remained independently predictive in the male. but not female, population. Conclusion: 
Women are at significantly higher risk for in-hospital NHCVA following MI, which is not 
explained by their greater prevalence of other risk factors. 
Variable Males OR [95% 
(7 
Females OR [95% Cl] 
EF < .40 1.58 [1.37-I.831 1.34 [1.18-1.531 
Q waves on admission EKG 1.38[1.14-1.68] 1.04 [O 84-l ,281 
ST elevation > 6 leads 1.51 [1.08-2.111 0.91 [0.60-l ,381 
Door to primary PTCA > 120 minutes 2.71 [1.63-4.511 1.22 [0.78-l ,911 
Door to thrombolyiic > 45 minutes 1.74 [1.17-2.601 1.27 [0.80-2.011 
1146-113 Elevated Troponin I Is an Independent Prognostic 
Marker for Increased Mortality Even in Patients 
Hospitalized With Noncardiac Diagnoses 
Sved W. Bokhari, Curtiss T. Stinis, Jason A. Zell, Cyril Y. Leung, University of Califomia- 
Irvine Medical Center, Orange, CA 
Background: Numerous studies have shown Troponin I (Tnl) to be a valuable predictor 
of prognosis in acute coronary syndrome patients, but none has assessed the clinical 
significance of elevated Troponin I (~0.5 ngimL) in patients hospitalized with non-cardiac 
diagnoses. Methods: In a cross-sectional design, a total of 60 patients, 30 consecutive 
with elevated Troponin I (eTnl) and 30 consecutive with normal Troponin I (nTnl) hospi- 
talized with non-cardiac diagnoses were investigated. Prevalence Rate Ratio (PRR) was 
utilized to analyze all-cause mortality as the prlmaty end-point. Multinomial logistic 
regression analysis was utilized to adjust mortality data for variables that differed signifi- 
cantly between the two groups. Results: The mayor categories of the admitting diag- 
noses were pulmonary (eTnl = 8, nTnl = 9), sepsis (eTnl = 7, nTnl = l), neurological 
(eTnl = 6, nTnl = 9), gastrointestinal (eTnl = 7, nTnl = 6). and others (eTnl =2. nTnl = 5). 
There were no significant differences found between the two groups in terms of their total 
number of cardiac risk factors, previous history of coronary artery disease or coronary 
revascularization, baseline creatinine, hematocrit, cholesterol levels, and use of aspirin, 
beta-blockers, angiotensin converting enzyme Inhibitors, or statins. The eTnl group con- 
sisted of 57% males, compared to 67% males in the nTnl group (p = 0.01). Mean age in 
the eTnl group was 67.8 years compared to 59.8 years in the nTnl group (p = 0.047). Of 
the thirty patients with elevated Trill (mean = 2.10 +/- 0.52 SD), 12 (40%) died during 
index hospitalization as compared to zero deaths reported in patients with normal Tnl 
(mean = 0.04 +/- 0.007 SD), and this dlfference was significant (PRR = 2.7, 95% Cl = 
1.9-3.8, p < 0.0005). Despite differences in age and gender between the two groups, 
adjusted analysis revealed elevated Troponin I to be the only risk factor for mortality (p c 
0.0005 for Tnl; p = 0.9 for gender; p = 0.8 for age). Conclusion: We have shown for the 
first time that the elevated Tropomn I is an Independent prognostic marker for increased 
mortality even in the patients admitted with non-cardiac dlagnoses. There was a trend 
towards more patients with sepsis I” the elevated Troponin I group. 
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1147-92 Initial Results of the Guidelines Applied in Practice for 
improving Quality of Care Patients With Acute 
Myocardial Infarction: The Flint-Saginaw Cooperative 
Initiative of the American College of Cardiology 
Foundation, Greater Flint Health Coalition, and 
Michigan Peer Review Organization 
Rajendra H. Mehta, Cecelia K. Montoye. Jessica Faul, Dorothy Nagle, James Kure, 
Ethira] Raj, Peter Fattal, Mahamadali Amlani, Shire.2 Sherrif, Hameem Changhezi. 
Stephen Skorcz. Patricia Baker, Anthony DeFranco, Kim A. Eaale. on Behalf of ACC 
GAP Steering Committee, University of Michigan, Ann Arbor, Ml 
Background: Since tool use in GAP-Pilot Project resulted in high level of evidence. 
based therapies for pattents with acute myocardial infarctlon (Ml), we decided to test if 
major emphasis on process changes and tool use rather than focusing solely on improv- 
ing key Indicator rates would increase the use of evidence-based therapies. Methods 
The GAP-Flint-Saginaw Ml Initiative was modeled on GAP-Pilot Project in five area hos- 
pitals in Michigan with greater emphasis on tool use and continuous monitoring of tool 
use. This surveillance allowed for early identification of process changes, barriers, and 
reslstance to change. This in turn led to new rapld cycle plans to overcome barriers. Main 
outcome measures were Ml quality indicator use in pre- (l/1/01-6/30/01) and post- (12/ 
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15/01-3/31/02) measurement samples. Results: One or more tools were used in 93% of 
patients (standard orders=82%, critical pathways=79% and discharge document=44%). 
Indicator use is as shown (table). ‘=p<O.O5 compared to baseline. 
Indicators Baseline Remeasureme Remeasurement 
(1x523) nt (rl=499) (With tooI use) 
Withln 24 hours of hospital 
arrival 
Aspirin (%) 
Beta-blockers (%) 
LDL cholesterol measurement 
At discharge 
Asplrin (%) 
Beta-blockers (%) 
ACE inhibitors in patients with 
low LV dysfunction (%) 
Smoking cessation counseling 
(“~) 
Dietary counseling (%) 
Cholesterol lowering agents 
88.9 89.6 92.0 
71.8 71.6 72.0 
82.3 83.6 86.6 
78.8 90.9 93.4 
78.4 90.4 89.3 
69.2 88.8’ 93.7’ 
57.5 72.8’ 84.6’ 
78.1 
76.8 
88.8 95.4’ 
84.1 87.6 
Conclusions These data validate the results of GAP-Pilot Project that quality of MI care 
can be improved through emphasis on guideline-based tool use. Continuous monitoring 
of tool use and identifying/overcoming of barriers, lead to substantially higher tool use 
than observed in initial GAP project. Tool use is associated with higher adherence to key 
indicators, particularly key theraples at discharge. 
1147-93 Predictors of Treatment Delay in Patients With Acute 
Myocardial Infarction Undergoing Primary Angioplasty: 
An Analysis From the CADILLAC Trial 
Mark A. Turco, Martin Fahy, Roxana A. Mehran, Alexandra Lansky, Cindy L. Gr~nes, 
James E. Tcheng, Eulogio Garcia, Giulio Guagliumi, David A. Cox, Thomas D. Stuckey, 
Dawn E. Shaddinger, Gregg W. Stone, Center for Cardiac &Vascular Research and 
Washington Adventist Hospital, Takoma Park, MD, Cardiovascular Research Foundation 
and Lenox Hill Heart and Vascular Center, New York, NY 
Background: Delays in time to angioplasty after hospital arrival in patients (pts) under- 
going primary PCI for AMI have been associated with increased mortality in large data- 
bases. However, the inherent reasons and correlates for delay to angioplasty remain 
poorly understood. 
Methods: We analyzed the baseline demographic, angiographic, and procedure-related 
variables predictive of delays in door-to-balloon time (DB time) in the CADILLAC trial, in 
which 2,082 pts of any age with AMI onset cl2 hours (excluding shock) were randomized 
to PTCA vs stew, with vs without abciximab. 
Results: Median DB time was 120 minutes (interquartile range 90-l 62) for all pts. Statis- 
tically significant clinical predictors of delay > Phrs by univariate analysis included female 
gender (risk ratio 1.13, pcO.OOOl), circumflex infarction (RR 1.54, p<O.OOOl), insulin 
dependent diabetes (RR 2.22, p=O.O02), prior CABG (RR 3.28, p=O.O2), non-ST-eleva- 
tion Ml (RR 4.35. pcO.OOOl), 3 vessel disease (RR 1.30, p=O.O2), and delayed time to ER 
arrival (p=O.O003). Anglographic predictors of delay included pre-procedure TIMI- flow, 
small reference vessel diameter and larger initial MLD (all p<O.OOOl). Multtvariate predic- 
tors of delay using stepwise logistic regression Included non-LAD infarction (p=O.O4), 
female gender (p=O.O004), 3-vessel disease (p=O.O2), small reference vessel diameter 
(p<.OOOl), and larger initial MLD (p<O.OOOl). 
Conclusion: The time from hospital presentation to angioplasty IS >2hrs in 50% of pts 
with AMI undergoing contemporary interventional management. Predictors of delay to 
treatment after hospital arrival may be explained by atypical symptoms or indeterminate 
ECGs (female gender or LCX Ml), and less severe symptoms (smaller infarct vessel or 
patency of infarct vessel due to larger MLD). These data emphasize the need for aware- 
ness and expedited reperfusion pathways for patients at highest risk for delays to PCI. 
1147-94 Beneficial Effects of Direct Call to Emergency Medical 
Services on Time Delays and Management of Patients 
With Acute Myocardial Infarction: Real World Data From 
RICO Database 
Jean-Claude Beer, Gilles Dentan. Luc Janin-Manificat, Marianne Zeller, Yves Laurent, 
lsabelle Lhuillier, Jacques Ravisy Yves Cottin Jean-Eric Wolf, CHU Dijon, Dljon. France 2-1 
Background. Delayed access to medical care in patients with acute myocardial infarc- 
tion (AMI) increases myocardial damage. Only few studies have analysed the influence 
of direct call to emergency medical services (EMS) in patients with AMI. From the 
regional observatory of Ml (RICO) data base, we report the acute management in 
patients calling either EMS or other medical contact (OMC) as first medical seek after 
symptoms onset of Ml. Methods Data were prospectively collected from January to 
October 2001, in the 6 medical units in charge of Ml in the region of Cote d‘Or. Among 
the 322 patients included, only 57 (18%) directly called EMS after symptoms onset 
(group EMS) and 265 (82%) called another medical contact (group OMC). Results The 
baseline characteristics including age and risk factors were similar among the 2 groups 
of patients. Moreover, cardiovascular history was the same between the two groups, 
except for history of MI (21 % in EMS group vs 11 % I” OMC group, ~~0.05). The median 
tbmes from symptoms onset to first medical Intervention (48 vs 105 min, ~~0.02) and from 
